MIRA
INFORM REPORT
|
Report Date : |
03.12.2008 |
IDENTIFICATION
DETAILS
|
Name : |
BENTA SAL |
|
|
|
|
Registered Office : |
Benta
Building, Zouk El Khrab Area, Sin Fil, PO Box: 55191, Dbayeh |
|
|
|
|
Country : |
Lebanon |
|
|
|
|
Financials (as on) : |
31.12.2007 |
|
|
|
|
Year of Establishment : |
2004 |
|
|
|
|
Com. Reg. No.: |
2002750, Baabda |
|
|
|
|
Legal Form : |
Lebanese Joint Stock Company |
|
|
|
|
Line of Business : |
Production of pharmaceutical preparations |
RATING &
COMMENTS
|
MIRA’s Rating : |
Ba |
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
Maximum Credit Limit : |
US$ 250,000 |
|
|
|
|
Status : |
Satisfactory |
|
|
|
|
Payment Behaviour : |
No Complaints |
|
|
|
|
Litigation : |
Clear |
SUMMARY
Company Name : BENTA SAL
Also Known As : BENTA PHARMACEUTICAL INDUSTRIES (BPI)
Country of Origin : Lebanon
Legal Form : Lebanese Joint Stock Company
Registration Date : 2004
Commercial Registration Number : 2002750, Baabda
Issued Capital : LP 105,000,000
Paid up Capital : LP 105,000,000
Total Workforce : 140
Activities : Production of pharmaceutical preparations
Financial Condition : Fair
Payments : Nothing detrimental uncovered
Operating Trend : Steady
Recommended Credit Limit : US$ 250,000
COMPANY NAME
BENTA SAL
ALSO
KNOWN AS
BENTA
PHARMACEUTICAL INDUSTRIES (BPI)
ADDRESS
Registered & Physical
Address
Building : Benta
Building
Area : Zouk
El Khrab Area, Sin Fil
PO Box : 55191
Town : Dbayeh
Country : Lebanon
Telephone : (961-4) 541444
Facsimile : (961-4) 541333
Mobile : (961-3) 245583
Premises
Subject operates from
a medium sized suite of offices and a factory that are owned and located in the
Suburban Business Area of Dbayeh.
KEY PRINCIPALS
Name Position
·
Bernard
A Tannoury Managing
Director
·
Naji
A Tannoury Director
·
Albert
R Tannoury Director
·
Ms.
Samar H Matar Technical
Manager
LEGAL FORM & OWNERS
Date of Establishment : 2004
Legal Form :
Lebanese Joint Stock
Company
Commercial Reg. No. : 2002750, Baabda
Issued Capital : LP 105,000,000
Paid up Capital : LP 105,000,000
Name of Shareholder (s)
·
Bernard
A Tannoury
·
Naji
A Tannoury
·
Albert
R Tannoury
OPERATIONS
Activities: Engaged in the production of pharmaceutical preparations, including cardiovascular
products, stimulants and anti-depressive agents for the central nervous system,
pharmaceutical preparations for metabolism, and oncological preparations.
Import
Countries: France, Italy, Germany, Greece, Spain, Switzerland,
Austria, Sweden, Ireland, Japan, Thailand, South Korea, Canada, Mexico and the
United States of America
Brand Names: GLISODIN and
SUCCAREL
Operating Trend: Steady
Subject has a
workforce of approximately 140 employees.
FINANCIAL DATA
Financial
highlights provided by local sources are given below:
Currency: Lebanese
Pounds (LP)
Year
Ending 31/12/06: Year
Ending 31/12/07:
Total Sales LP 5,175,000,000 LP 6,000,000,000
Local sources
consider subject’s financial condition to be Fair.
The above financial
figures are based on estimations by our local sources.
BANKERS
·
Byblos Bank
Sal
PO Box : 115605
Beirut
Tel : (961-1) 898200
Fax : (961-1) 898209
·
Credit
Bancaire Sal
PO Box : 165795
Beirut
Tel : (961-1) 218183 / 200489
Fax : (961-1) 200483
·
HSBC Bank
Middle East
PO Box : 111380
Beirut
Tel : (961-1) 425296
Fax : (961-1) 425295
PAYMENT HISTORY
No complaints
regarding subject’s payments have been reported.
GENERAL COMMENTS
During the course
of this investigation nothing detrimental was uncovered regarding subject’s
operating history or the manner in which payments are fulfilled. As such the
company is considered to be a fair trade risk.
FOREIGN EXCHANGE
RATES
|
Currency |
Unit
|
Indian Rupees |
|
US Dollar |
1 |
Rs.49.90 |
|
UK Pound |
1 |
Rs.74.30 |
|
Euro |
1 |
Rs.63.42 |
RATING
EXPLANATIONS
|
RATING |
STATUS |
PROPOSED CREDIT LINE |
|
|
>86 |
Aaa |
Possesses an extremely sound financial base with the strongest
capability for timely payment of interest and principal sums |
Unlimited |
|
71-85 |
Aa |
Possesses adequate working capital. No caution needed for credit
transaction. It has above average (strong) capability for payment of interest
and principal sums |
Large |
|
56-70 |
A |
Financial & operational base are regarded healthy. General unfavourable
factors will not cause fatal effect. Satisfactory capability for payment of
interest and principal sums |
Fairly Large |
|
41-55 |
Ba |
Overall operation is considered normal. Capable to meet normal
commitments. |
Satisfactory |
|
26-40 |
B |
Unfavourable & favourable factors carry similar weight in credit
consideration. Capability to overcome financial difficulties seems
comparatively below average. |
Small |
|
11-25 |
Ca |
Adverse factors are apparent. Repayment of interest and principal sums
in default or expected to be in default upon maturity |
Limited with
full security |
|
<10 |
C |
Absolute credit risk exists. Caution needed to be exercised |
Credit not
recommended |
|
NR |
In view of the lack of information, we have no basis upon which to
recommend credit dealings |
No Rating |
|
This score serves as a reference to assess SC’s credit risk
and to set the amount of credit to be extended. It is calculated from a composite
of weighted scores obtained from each of the major sections of this report. The
assessed factors and their relative weights (as indicated through %) are as
follows:
Financial
condition (40%) Ownership
background (20%) Payment
record (10%)
Credit history
(10%) Market trend
(10%) Operational
size (10%)